LONDON – Ipsen SA has followed up an equity investment in Syntaxin Ltd with a research collaboration that will net the UK botulinum toxin specialist $9 million over three years for discovery work, with additional fees for any compounds that go into development, and a potential further $90 million in commercial milestones.